XML 50 R30.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Long-Term Investments (Tables) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2023 | Dec. 31, 2022
Long-Term Investments [Abstract] |  |
Schedule of Ownership Percentages of Each Investee | The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | September 30, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2023 |  |  | 2022 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.22 | % |  |  | 0.22 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.92 | % |  |  | 0.92 | % |  | Cost Method
BioHopeKing Corporation |  |  | 8.03 | % |  |  | 8.03 | % |  | Cost Method
BioFirst Corporation |  |  | 23.53 | % |  |  | 21.77 | % |  | Equity Method
Rgene Corporation |  |  | 28.85 | % |  |  | 28.85 | % |  | Equity Method
| The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | December 31, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2022 |  |  | 2021 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.22 | % |  |  | 0.22 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.92 | % |  |  | 0.92 | % |  | Cost Method
BioHopeKing Corporation |  |  | 8.03 | % |  |  | 8.03 | % |  | Cost Method
BioFirst Corporation |  |  | 21.77 | % |  |  | 21.77 | % |  | Equity Method
Rgene Corporation |  |  | 28.85 | % |  |  | 28.85 | % |  | Equity Method
Schedule of Extent the Investee Relies | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
| The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from the investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
Schedule of Long-Term Investment | Long-term investment mainly consists of the following:
|  | September 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 6,838 |  |  | $ | 7,169 |
Genepharm Biotech Corporation |  |  | 20,876 |  |  |  | 21,887 |
BioHopeKing Corporation |  |  | 775,491 |  |  |  | 813,014 |
Sub total |  |  | 803,205 |  |  |  | 842,070 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | 1,874,190 |  |  |  | - |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 2,677,395 |  |  | $ | 842,070 |
| Long-term investment mainly consists of the following:
|  | December 31, 2022 |  |  | December 31, 2021 |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,169 |  |  | $ | 7,941 |
Genepharm Biotech Corporation |  |  | 21,887 |  |  |  | 24,244 |
BioHopeKing Corporation |  |  | 813,014 |  |  |  | 900,570 |
Subtotal |  |  | 842,070 |  |  |  | 932,755 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | - |  |  |  | - |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 842,070 |  |  | $ | 932,755 |
Schedule of Balance Sheet | Balance Sheet
|  | September 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 1,690,060 |  |  | $ | 1,543,152 |
Non-current Assets |  |  | 651,221 |  |  |  | 739,472 |
Current Liabilities |  |  | 2,236,708 |  |  |  | 2,663,051 |
Non-current Liabilities |  |  | 366,634 |  |  |  | 103,447 |
Stockholders’ Equity (Deficit) |  |  | (262,061 | ) |  |  | (483,874 | )
|  | September 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 56,091 |  |  | $ | 68,302 |
Non-current Assets |  |  | 239,594 |  |  |  | 303,893 |
Current Liabilities |  |  | 2,407,204 |  |  |  | 2,478,868 |
Non-current Liabilities |  |  | 1,465 |  |  |  | 2,441 |
Shareholders’ Deficit |  |  | (2,112,984 | ) |  |  | (2,109,114 | )
| Balance Sheet
|  | December 31, 2022 |  |  | December 31, 2021 |
Current Assets |  | $ | 1,543,151 |  |  | $ | 2,205,669 |
Noncurrent Assets |  |  | 739,472 |  |  |  | 959,454 |
Current Liabilities |  |  | 2,663,051 |  |  |  | 2,909,703 |
Noncurrent Liabilities |  |  | 103,447 |  |  |  | 32,522 |
Stockholders’ Equity |  |  | 483,874 |  |  |  | 222,898 |
|  | December 31, 2022 |  |  | December 31, 2021 |
Current Assets |  | $ | 68,302 |  |  | $ | 73,452 |
Noncurrent Assets |  |  | 303,893 |  |  |  | 374,423 |
Current Liabilities |  |  | 2,478,868 |  |  |  | 1,934,786 |
Noncurrent Liabilities |  |  | 2,441 |  |  |  | - |
Shareholders’ Deficit |  |  | (2,481,309 | ) |  |  | (1,486,911 | )
Schedule of Statement of Operation | Statement of Operations
|  | Nine months Ended September 30, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Net sales |  | $ | 739 |  |  | $ | 23,079 |
Gross profit |  |  | 291 |  |  |  | 5,747 |
Net loss |  |  | (986,181 | ) |  |  | (993,643 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  | - |
|  | Nine months Ended September 30, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (231,445 | ) |  |  | (450,995 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
| Statement of operation
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Net sales |  | $ | 30,162 |  |  | $ | 26,693 |
Gross profit |  |  | 8,239 |  |  |  | 8,348 |
Net loss |  |  | (1,274,539 | ) |  |  | (2,276,892 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  | (269,844 | )
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (1,550,123 | ) |  |  | (576,514 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
Schedule of Components of Losses on Equity Investments | The components of losses on equity investments for each period were as follows:
|  |  | Nine months Ended September 30, |
|  |  | 2023 |  |  |  | 2022 |
|  |  | (Unaudited) |
Share of equity method investee losses |  | $ | - |  |  | $ | - |
| The components of losses on equity investments for each period were as follows:
|  | Year Ended December 31, |
|  | 2022 |  |  | 2021 |
Share of equity method investee losses |  | $ | - |  |  | $ | (269,844 | )

X
- Definition Schedule of extent the investee relies. + References No definition available. + Details
Name: | abvc_ScheduleOfExtentInvesteeReliesTableTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_ScheduleOfLongTermInvestmentTableTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph (a) -Publisher SEC Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_LongTermInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration